← Product Code [DHA](/submissions/CH/subpart-b%E2%80%94clinical-chemistry-test-systems/DHA) · K042676

# NICHOLS ADVANTAGE HYPERGLYCOSYLATED HUMAN CHORIONIC GONADOTROPIN (H-HCG) ASSAY (K042676)

_Nichols Institute Diagnostics · DHA · Dec 17, 2004 · Clinical Chemistry · SESE_

**Canonical URL:** https://fda.innolitics.com/submissions/CH/subpart-b%E2%80%94clinical-chemistry-test-systems/DHA/K042676

## Device Facts

- **Applicant:** Nichols Institute Diagnostics
- **Product Code:** [DHA](/submissions/CH/subpart-b%E2%80%94clinical-chemistry-test-systems/DHA.md)
- **Decision Date:** Dec 17, 2004
- **Decision:** SESE
- **Submission Type:** Traditional
- **Regulation:** 21 CFR 862.1155
- **Device Class:** Class 2
- **Review Panel:** Clinical Chemistry
- **Attributes:** 3rd-Party Reviewed

## Indications for Use

The Nichols Advantage Hyperglycosylated Human Chorionic Gonadotropin (H-hCG) Assay (or simply: Nichols Advantage® H-hCG Assay) is intended for use with the Nichols Advantage® Specialty System for the quantitative measurement of hyperglycosylated human chorionic gonadotropin (H-hCG), a placental hormone in human serum, or for the qualitative determination of H-hCG in urine as an aid in the detection of pregnancy. These diagnoses should be made with appropriate additional clinical evidence. Clinical considerations and professional judgment should be applied to any test device result, particularly when preliminary positive results are obtained, as with this Nichols H-hCG chemiluminescent immunoassay. The Nichols Advantage® H-hCG Assay is used in conjunction with two H-hCG calibrators which are used to calibrate the assay and are provided separately to the reagent cartridge. The control is used for the monitoring of the accuracy and precision of the Nichols Advantage H-hCG Assay and successful calibration is confirmed using three H-hCG controls also provided separately to the calibrators and reagent cartridge.

## Device Story

The Nichols Advantage H-hCG Assay is a two-step, two-site immunochemiluminometric sandwich assay performed on the Nichols Advantage Specialty System. It utilizes biotinylated mouse monoclonal anti-H-hCG antibodies (B152) for capture and acridinium ester-labeled mouse monoclonal anti-H-hCG antibodies (B207) for detection. Streptavidin-coated magnetic particles (Dynabeads) facilitate separation. The system processes human serum or urine samples, incubating them at 37°C. The device produces quantitative results in ng/mL for serum and qualitative results for urine. It is intended for use in clinical laboratory settings. Healthcare providers use the results, in conjunction with other clinical evidence, to aid in pregnancy detection. The assay provides a diagnostic aid by measuring hyperglycosylated hCG, a placental hormone, allowing for early pregnancy assessment.

## Clinical Evidence

No clinical data. Performance was established through bench testing, including precision (NCCLS EP5-A), linearity, recovery, and high-dose hook effect studies. Precision studies across five systems showed total CVs ranging from 5.0% to 7.4%. Linearity was confirmed up to 300 ng/mL (R-square 0.9986). Recovery studies demonstrated 89-102% recovery. High-dose hook effect was evaluated up to 31,000 ng/mL.

## Technological Characteristics

Two-step immunochemiluminometric assay. Components: streptavidin-coated magnetic particles, biotinylated rabbit anti-mouse anti-H-hCG, acridinium ester-labeled mouse anti-H-hCG. Energy source: chemiluminescent reaction triggered by system luminometer. Form factor: reagent cartridge for automated analyzer. Connectivity: uses lot-specific master curve bar code card. Standard: NCCLS EP5-A for precision.

## Regulatory Identification

A human chorionic gonadotropin (HCG) test system is a device intended for the early detection of pregnancy is intended to measure HCG, a placental hormone, in plasma or urine. A human chorionic goadotropin (HCG) test system is a device intended for any uses other than early detection of pregnancy (such as an aid in the diagnosis, prognosis, and management of treatment of persons with certain tumors or carcinomas) is intended to measure HCG, a placental hormone, in plasma or urine.

## Predicate Devices

- IMMULITE® hCG Assay (k990222)

## Submission Summary (Full Text)

> This content was OCRed from public FDA records by [Innolitics](https://innolitics.com). If you use, quote, summarize, crawl, or train on this content, cite Innolitics at https://innolitics.com.
>
> Innolitics is a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices, including [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/).

{0}

1

# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY ONLY TEMPLATE

A. 510(k) Number:
k042676

B. Purpose for Submission:
New device

C. Measurand:
Human chorionic gonadotropin

D. Type of Test:
Quantitative and qualitative, Immunochemiluminometric assay

E. Applicant:
Nichols Institute Diagnostics

F. Proprietary and Established Names:
Nichols Advantage® Hyperglycosylated Human Chorionic Gonadotropin (H-hCG) Assay; Nichols Advantage® Hyperglycosylated Human Chorionic Gonadotropin Calibrators; and Nichols Advantage® Hyperglycosylated Human Chorionic Gonadotropin Controls

G. Regulatory Information:

1. Regulation section:
21 CFR 862.1155, Human chorionic gonadotropin (HCG) test system
21 CFR 862.1150, Calibrator
21 CFR 862.1660, Quality control material (assayed and unassayed)

2. Classification:
Class II (hCG test system and calibrator), Class I (quality control material)

{1}

3. Product code:

DHA (hCG test system), JIT (calibrator), JJX (quality control material)

4. Panel:

Chemistry (75)

H. Intended Use:

1. Intended use(s):

The Nichols Advantage Hyperglycosylated Human Chorionic Gonadotropin (H-hCG) Assay (or simply: Nichols Advantage® H-hCG Assay) is intended for use with the Nichols Advantage® Specialty System for the quantitative measurement of hyperglycosylated human chorionic gonadotropin (H-hCG), a placental hormone in human serum, or for the qualitative determination of H-hCG in urine as an aid in the detection of pregnancy. These diagnoses should be made with appropriate additional clinical evidence. Clinical considerations and professional judgment should be applied to any test device result as with this Nichols H-hCG chemiluminescent immunoassay.

The Nichols Advantage Hyperglycosylated Human Chorionic Gonadotropin Calibrators are intended for adjustment of the stored curve for Nichols Advantage® Hyperglycosylated Human Chorionic Gonadotropin (H-hCG) Assay.

The Nichols Advantage Hyperglycosylated Human Chorionic Gonadotropin (H-hCG) Controls are intended for use as an assayed quality control solution to monitor the accuracy and precision of the Nichols Advantage H-hCG Immunoassay.

2. Indication(s) for use:

The Nichols Advantage Hyperglycosylated Human Chorionic Gonadotropin (H-hCG) Assay (or simply: Nichols Advantage® H-hCG Assay) is intended for use with the Nichols Advantage® Specialty System for the quantitative measurement of hyperglycosylated human chorionic gonadotropin (H-hCG), a placental hormone in human serum, or for the qualitative determination of H-hCG in urine as an aid in the detection of pregnancy. These diagnoses should be made with appropriate additional clinical evidence. Clinical considerations and professional judgment should be applied to any test device result as with this Nichols H-hCG chemiluminescent immunoassay.

The Nichols Advantage® H-hCG Assay is used in conjunction with two H-hCG calibrators which are used to calibrate the assay and are provided separately to the reagent cartridge. The control is used for the monitoring of the accuracy and

2

{2}

precision of the Nichols Advantage H-hCG Assay and successful calibration is confirmed using three H-hCG controls also provided separately to the calibrators and reagent cartridge.

3. Special conditions for use statement(s):

This device is for clinical laboratory use only and for prescription use only.

4. Special instrument requirements:

Nichols Advantage® Specialty System

I. Device Description:

The Nichols Advantage H-hCG Assay is composed of the following materials:

- One cartridge with the following reagents sufficient for 100 tests: one vial containing streptavidin-coated magnetic particles in PBS buffer and preservatives
- One vial containing acridinium ester-labeled mouse anti-H-hCG antibody solution
- One vial containing biotinylated rabbit anti-mouse anti-H-hCG antibody solution
- One vial of heat-treated mouse serum with preservative
- Diluent
- Assay Buffer
- One lot specific H-hCG Master Curve Bar Code Card

Calibrators and controls are required but are sold separately. The two calibrators are each supplied in four 1.0 mL vials, each containing lyophilized buffered protein solution with preservative. The target concentrations are as follows: Cal A (1.0 ng/mL) and Cal B (100 ng/mL). The three controls are each supplied in four 1.0 mL vials, each containing H-hCG in a lyophilized buffered protein solution with preservative. The target concentrations are as follows: Level 1 (2.0 ng/mL), Level 2 (20 ng/mL), and Level 3 (200 ng/mL).

The calibrators and controls contain materials of human origin which have been tested using FDA approved methods and have been found negative for antibodies to Human Immunodeficiency Virus (HIV I and HIV II) and to Hepatitis C Virus (HCV), as well as for Hepatitis B surface antigen (HBsAg).

J. Substantial Equivalence Information:

1. Predicate device name(s):

IMMULITE® hCG Assay

{3}

2. Predicate 510(k) number(s):

k990222

3. Comparison with predicate:

|  Similarities  |   |   |
| --- | --- | --- |
|  Item | Device | Predicate  |
|  Antibody Recognition | Specific antibodies that bind isoforms of hCG | Same  |
|  Sample Type | Human serum or urine | Same  |
|  Analysis Technology | Utilizes chemiluminescent technology for quantitation with assay incubated to 37°C. | Same  |
|  Differences  |   |   |
| --- | --- | --- |
|  Item | Device | Predicate  |
|  Capture/Detection Material | Biotinylated and acridinium ester-labeled mouse monoclonal anti-H-hCG antibodies coated on magnetic particles | Monoclonal antibody coated polystyrene bead  |
|  Sample Volume | 15 microliters | 5 microliters  |
|  Standardization | C5 antigen of Elliott et al. | WHO 3rdI.S.  |
|  Reporting Unit | ng/ml [based on Mass units of ng per ml serum] | mIU/ml [based on milli-International Units]  |

# K. Standard/Guidance Document Referenced (if applicable):

NCCLS EP5-A

# L. Test Principle:

The Nichols Advantage H-hCG Assay is a two-step, two-site immunochemiluminometric assay. Sample, biotinylated-B152 anti-H-hCG antibodies, and streptavidin-coated magnetic particles are allowed to incubate. Unbound assay components and other sample constituents are separated from the complex bound to the magnetic particles by aspiration of the reaction mixture and subsequent washing. Acridinium-labeled anti-H-hCG antibodies are added, creating the sandwich complex. The magnetic particles are washed and transported into the system luminometer, which injects Triggers 1 and 2, initiating the chemiluminescent reaction. The luminometer quantitates the light and expresses it as relative light unit (RLU). The signal is directly proportional to the concentration of H-hCG in the sample. The

{4}

quantity of H-hCG in the sample is determined by comparing the signal of the sample to that of a known standard.

# M. Performance Characteristics (if/when applicable):

# 1. Analytical performance:

# a. Precision/Reproducibility:

To evaluate precision, the within-run and total precision of the Nichols Advantage H-hCG Assay was calculated using the NCCLS EP5-A method (Evaluation of Precision Performance of Clinical Chemistry Devices; Approved Guideline). Serum pools and controls were tested in duplicate in two runs per day over 6 days. The study used five Nichols Advantage Specialty Systems. The results were as follows:

|  Sample | Mean (ng/mL) | Within-Run |   | Total Precision  |   |
| --- | --- | --- | --- | --- | --- |
|   |   |  SD | %CV | SD | %CV  |
|  1 | 3.0 | 0.10 | 3.4 | 0.16 | 5.4  |
|  2 | 9.0 | 0.16 | 1.8 | 0.45 | 5.0  |
|  3 | 27.7 | 0.92 | 3.3 | 1.38 | 5.0  |
|  4 | 44.8 | 2.36 | 5.3 | 2.82 | 6.3  |
|  5 | 173 | 5.88 | 3.4 | 12.75 | 7.4  |

# b. Linearity/assay reportable range:

The highest reportable value without dilution is the value of the highest point on the Master Curve (300 ng/mL). The following studies were performed to support linearity.

# Parallelism

Samples with varying concentrations of H-hCG were either manually diluted with Sample Diluent before placing onto the system or diluted on-board the system. The observed and corrected results are presented. The results demonstrate linearity across the dynamic range of this Nichols Advantage H-hCG Assay.

|  Serum Sample | Dilution | Observed (ng/mL) | Expected (ng/mL) | % Recovery  |
| --- | --- | --- | --- | --- |
|  1 | Undiluted | 12.2 |  |   |
|   | 1:2 | 6.7 | 6.1 | 110  |
|   | 1:4 | 3.3 | 3.1 | 106  |

{5}

6

|  |   |   |   |   |
| --- | --- | --- | --- | --- |
|  2 | Undiluted | 70.1 |  |   |
|   | 1:2 | 35.2 | 35.1 | 100  |
|   | 1:4 | 19.1 | 17.5 | 109  |
|   | 1:8 | 9.0 | 8.8 | 102  |
|  3 | Undiluted | 135.6 |  |   |
|   | 1:2 | 69.5 | 67.8 | 103  |
|   | 1:4 | 37.1 | 33.9 | 109  |
|   | 1:8 | 19.6 | 17.0 | 115  |

Recovery

Three sets of a high and a low/normal serum samples were mixed in 2:1, 1:1 and 1:2 ratios and assayed. The recoveries were determined from the undiluted results. The results demonstrate recovery of H-hCG in patients' samples between 89 and 102%.

|  Serum Sample | Observed (ng/mL) | Expected (ng/mL) | % Recovery  |
| --- | --- | --- | --- |
|  Sample A | 135.6 |  |   |
|  2 : 1 | 86.6 | 97.0 | 89  |
|  1 : 1 | 75.2 | 77.7 | 97  |
|  1 : 2 | 55.6 | 58.4 | 95  |
|  Sample B | 19.8 |  |   |
|  Sample C | 154.4 |  |   |
|  2 : 1 | 103.0 | 106.5 | 97  |
|  1 : 1 | 74.1 | 82.6 | 90  |
|  1 : 2 | 55.7 | 58.6 | 95  |
|  Sample D | 10.7 |  |   |
|  Sample E | 82.9 |  |   |
|  2 : 1 | 60.2 | 59.1 | 102  |
|  1 : 1 | 44.8 | 47.3 | 95  |
|  1 : 2 | 33.9 | 35.4 | 96  |
|  Sample F | 11.6 |  |   |

Dilution and recovery of a pooled serum sample at 285 ng/mL H-hCG was performed and yielded an average recovery of 103.8%. See the table below:

|  Sample 285.5 ng/mL | Dose (ng/mL) | Corrected dose (ng/mL) | % Recovery  |
| --- | --- | --- | --- |
|  1 : 2 | 148.7 | 297.4 | 104.2  |
|  1 : 4 | 73.4 | 293.6 | 102.8  |
|  1 : 8 | 37.0 | 296.0 | 103.7  |
|  1:10 | 29.8 | 298.0 | 104.4  |

{6}

The high dose hook effect for the Nichols Advantage H-hCG Assay was determined to be greater than 31,000 ng/mL. Linear regression analysis within the dynamic range (up to 300 ng/mL) yielded an R-square value of 0.998647. See graph below.

Linear Regression Analysis (Within Dynamic Range)

Response RLU Unit and Regression Plot

7

---

**Source:** [https://fda.innolitics.com/submissions/CH/subpart-b%E2%80%94clinical-chemistry-test-systems/DHA/K042676](https://fda.innolitics.com/submissions/CH/subpart-b%E2%80%94clinical-chemistry-test-systems/DHA/K042676)

**Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact).

**Cite:** Innolitics at https://innolitics.com